Significant improvement in Salivary Gland Ultrasound Scores after treatment with rituximab 

In patients with primary Sjogren's syndrome, improvements in salivary gland ultrasound were demonstrated after treatment with rituximab, according to the results of the TRACTISS randomised double-blind multicentre substudy published in the Annals of the Rheumatic Diseases in 2018.

A total of 52 patients (26 treated with rituximab and 26 treated with placebo) from 9 centers completed the baseline visit and 1 or more follow-up visits.

The research showed statistically significant improvement in total ultrasound score (TUS) after rituximab compared with the placebo. 

 rituximab with a peptide epitope